ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-FAP Antibody-drug Conjugate OMTX705

Its studies are led by Oncomatryx Biopharma S.L.

Furthest: phase 1, since Jun 2, 20222 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oncomatryx Biopharma S.L.22 open or runningphase 1since Jun 2, 2022Jun 2, 2022Dec 2027phase 1 · NCT05547321

Also a collaborator on its studies: Certara, Biotrial and Clinigen.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 2, 2022First study: phase 1 study in Advanced Solid TumorFirst studyNCT05547321 · 150 planned · United States, Spain
  2. Dec 1, 2025Phase 1 study in Pancreatic Adenocarcinoma MetastaticNCT07377045 · 69 planned · United States, Spain

Ahead

  1. Dec 2027Primary completion: phase 1 study in Advanced Solid TumorNCT05547321
  2. Mar 2029Primary completion: phase 1 study in Pancreatic Adenocarcinoma MetastaticNCT07377045

TargetBeta

FAP →read by rule
“An antibody-drug conjugate (ADC) composed of OMTX005, a humanized monoclonal antibody directed against fibroblast activation protein (FAP), ”NCIt, by rule

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FAPI-74rulesofiephase 33
Fluorine F 18 FPyQCPruleBraccophase 21
HRS-6768Jiangsu HengRui Medicinephase 21
Gallium Ga 68 NNS309Novartisphase 12
Actinium Ac 225 RTX-2358ruleratio-therapeutics-incphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07377045Pancreatic Adenocarcinoma Metastatic · United States, Spain1RecruitingMar 202969
NCT05547321Advanced Solid Tumor · United States, Spain1RecruitingDec 2027150

How it is read

Names in the registry

  • “OMTX705”, 6 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.